DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak

CARLSBAD, California, June 2, 2011 -

- Further analysis on Ion PGM(TM) will confirm data with goal to develop
accurate testing kits to screen samples

Life Technologies Corporation today announced that preliminary data from
DNA sequencing performed in cooperation with the University Hospital
Muenster, Germany, on the Ion Personal Genome Machine (PGM(TM)) strongly
suggests that the bacterium at the root of the deadly outbreak in Germany is
a new hybrid type of pathogenic E. coli strains.

The data obtained from the DNA sequencer shows the presence of genes
typically found in two different types of E. coli: enteroaggregative E. coli
(EAEC) and enterohemorrhagic E. coli (EHEC). These results, which are being
confirmed by further data analysis on the Ion PGM(TM), may provide insight
into this bacterium's aggressiveness and help prevent further outbreaks.

"The rapid whole genome sequencing results enabled us to discover within
days a unique combination of virulence traits … and makes this German
outbreak clone a unique hybrid of different E. coli pathovars," said Dr. med.
Alexander Mellmann, scientist at the German National Consulting Laboratory
for Hemolytic Uremic Syndrome (HUS) at the Institute of Hygiene, University
Hospital Muenster.

The data gathered at Life Technologies' laboratories in Darmstadt,
Germany, will be used by scientists at the University Hospital Muenster, to
develop better tests to positively identify the illness in people showing
symptoms of the infection, which includes kidney failure and bloody diarrhea.
For the first time since the outbreak, it is now possible to study in detail
the basis for what makes this strain so aggressive.

Life Technologies' Simone Guenther, Ph.D., who carried out the sequencing
work, said: "The severity of this outbreak meant that speed was of the
essence. We were able to provide the data in record time to University
Hospital Muenster. In previous outbreaks it would have taken much longer to
reach this stage."

To prevent further spreading of the bacterium, Life Technologies began
shipping its custom E. coli testing kits to European laboratories this week
to screen contaminated food thought to be at the center of the outbreak that
has killed 17 people and affected more than 1,000 in Europe.

The kits serve as a first line of defense to detect the presence of
pathogenic E. coli. Secondary testing is then performed using more specific
kits. Life Technologies will develop new customized kits specifically
designed to detect the hybrid strain in Germany once the sequencing data has
been fully analyzed in the next few days. The company can design custom
assays in less than one week.

The kits shipped to Europe are part of a large offering of molecular
tests developed by Life Technologies capable of accurately detecting most
pathogens that are dangerous to humans. The Ion PGM(TM) is a DNA sequencing
instrument featuring semiconductor technology that can complete a highly
accurate sequence of DNA in just two hours. The DNA sample used for the
sequencing work was collected from a patient with the illness.

The Ion Personal Genome Machine sequencer is for research use only. Not
for use in diagnostic procedures.

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation is a global biotechnology company dedicated
to improving the human condition. Our systems, consumables and services
enable researchers to accelerate scientific and medical advancements that
make life even better. Life Technologies customers do their work across the
biological spectrum, working to advance the fields of discovery and
translational research, molecular medicine, stem cell-based therapies, food
safety and animal health, and 21st century forensics. The company
manufactures both molecular diagnostic and research use only products. Life
Technologies' industry-leading brands are found in nearly every life sciences
lab in the world and include innovative instrument systems under the Applied
Biosystems and Ion Torrent names, as well as, the broadest range of reagents
with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan(R) products.
Life Technologies had sales of $3.6 billion in 2010, has a workforce of
approximately 11,000 people, has a presence in approximately 160 countries,
and possesses one of the largest intellectual property estates in the life
sciences industry, with approximately 3,900 patents and exclusive licenses.
For more information on how we are making a difference, please visit our
website: www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited to,
statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause
actual results or events to differ materially from those expressed or implied
by such forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual
results to differ materially from those in the forward-looking statements are
detailed in filings made by Life Technologies with the Securities and
Exchange Commission. Life Technologies undertakes no obligation to update or
revise any such forward-looking statements to reflect subsequent events or
circumstances.

(Logo: photos.prnewswire.com/prnh/20110216/MM49339LOGO)

    Life Technologies Contact
    Mauricio Minotta
    +1-760-929-2456
    Mauricio.minotta@lifetech.com

.